Morning Brief — Monday, August 17, 2026

Market Overview

Equity futures are mixed pre-bell with ETFs slightly higher as markets process a wave of retail earnings (WMT, HD, LOW, TGT all reported with muted reactions) and lower rate-hike expectations provide a modest tailwind. AI infrastructure names continue to dominate the narrative — Nebius (NBIS) is catching fresh institutional and retail attention as data center pricing remains elevated, while the Anthropic $200B revenue pitch is keeping sentiment frothy in the AI compute space. The broader tape feels like a rotational market: defensive/dividend names outperforming YTD while select small-cap catalysts generate outsized single-day moves.

Claude’s Call

UP — The path of least resistance is modestly higher today. Lower rate-hike expectations remove a key headwind, AI infrastructure sentiment remains constructive with NBIS/CBRS leading, and the retail earnings disappointments were mild enough not to spook the tape. Expect a grind higher with leadership in tech/AI and lagging consumer discretionary.

Top Movers

ETON (+44.3%) — $58.86 → $72.71 (+23.5% upside) Thesis: This is a genuine fundamental catalyst — Eton smashed Q2 revenue expectations with $37.59M (implied ~99% YoY growth) and raised full-year 2026 guidance from $120M+ to $145M+, with at least one analyst calling the new guidance “conservative.” The shift from net loss to profitability is the re-rating trigger here, and the stock is now at a 6-month AND all-time high. RSI at 50 suggests this isn’t yet technically overbought despite the enormous move — the sharp gap higher reset the RSI baseline. That said, with vol_vs_avg at just 0.2x, conviction on the day’s move is thinner than you’d like. Levels: Exit at fib 1.272 extension of $72.71. Nearest meaningful support is fib 23.6% at $50.34 — a long way down if sentiment shifts. The 50 SMA at $39.46 is the disaster-scenario floor.

⚠️ Reality check: 261% YTD gain going into this print, now another 44% on top. At some point the easy money is made. New buyers here are paying a steep premium for what an analyst thinks is conservative guidance. Wait for a pullback to the $50-$53 zone before adding.

HTFL (+35.7%) — $42.08 → $47.95 (+13.9% upside) Thesis: HeartFlow delivered 48% revenue growth in Q2 with a raised full-year outlook, earning a fair value bump from ~$37 to ~$42 from analysts — which means the stock is now trading right at the revised fair value. The AI-driven coronary diagnostics platform has real secular tailwinds (non-invasive cardiac imaging replacing invasive catheterization), but multiple analysts are already flagging this as “fully valued” after a 69% 30-day surge. This is a great business at a demanding price. Levels: Fib 1.272 extension at $47.95 is the logical exit target if momentum carries. First support at fib 23.6% of $36.98; the 50 SMA at $29.31 is the true floor. Vol ratio of 0.2x is concerning — this move happened on thin volume.

⚠️ Reality check: 46% on a day the fair value estimate barely moved above where it’s trading now. You’re chasing here. The risk/reward is poor for new entries — wait for a retest of $36-$37 fib support for a better setup.

AAOI (+15.5%) — $150.28 → $180.70 (+20.2% upside) Thesis: Applied Optoelectronics is riding two real catalysts: a multi-year supply agreement with Amazon and legitimate AI-driven optical networking demand as copper hits physical bandwidth limits. The CFO is presenting at Rosenblatt’s tech summit tomorrow (August 18), which could bring fresh institutional coverage. Vertical integration + expanding margins + hyperscaler contract = a real story. The stock is well off its 6-month high of $223, currently sitting between the fib 38.2% support ($154.47) and 50% support ($133.27) — the bounce has technical merit. Levels: Exit at fib 23.6% of $180.70 (prior resistance zone). Support at $133.27 (fib 50%) and the 50 SMA at $132.84 — these two nearly coincide, making it a strong technical floor. Be aware one article flags potential 93% overvaluation based on DCF. ⚠️ Watch the Rosenblatt presentation tomorrow for a potential catalyst-driven gap.

ARGX (+13.2%) — $963.41 → $1,052.67 (+9.2% upside) Thesis: argenx is a legitimate large-cap biotech compounder making an acquisition move — a $2.2B deal for Forte Biosciences (FB102, an anti-CD122 antibody) adds a first-in-class immunology asset to an already strong efgartigimod platform. This is strategic M&A, not a hype play, and argenx has the balance sheet credibility to execute. At $963, the stock is at a 6-month high with RSI at 50 (room to run technically). The 13% single-day move on an M&A announcement is standard for the acquiring side — the market is validating the deal. Levels: Exit at fib 1.272 extension of $1,052.67. Support at 23.6% fib of $897.42; SMA 50 at $880.14 acts as a secondary floor.

CBRS (+12.8%) — $246.97 → $277.43 (+12.3% upside) Thesis: Cerebras reported record Q2 revenue with core revenue up 103% YoY to $209.9M and an RPO (remaining performance obligations) of $25.4 billion — that backlog is the real story. New AWS and AMD collaborations expand distribution. However, the stock actually fell 12% post-earnings last week before today’s recovery bounce, suggesting the Q3 guidance disappointed initially. Today’s move is a “buy the post-earnings dip” trade, not a fresh breakout. The Wedbush note on rising data center pricing is providing fresh fuel. Levels: Resistance at fib 23.6% of $277.43 — that’s your exit target. Current price sits between SMA50 ($209.38) and the 20-day high ($262.06). The 6-month high of $311.07 is the longer-term target if the AI pricing narrative holds.

AEHR (+8.7%) — $134.06 → $162.78 (+21.4% upside) Thesis: Aehr Test Systems secured a $22M follow-on production order from a major AI processor customer (almost certainly NVIDIA or an equivalent), which is a concrete revenue event — not hype. The stock is at a 6-month high with 500%+ YTD gains and a fresh Street initiation with a reportedly “conservative” price target. CEO insider selling ($5.2M, ~10% of holdings) is a yellow flag, but doesn’t change the demand picture. Peer FormFactor (FORM) also popped 6% in sympathy, validating the WLBI demand thesis. Levels: Exit at fib 1.272 extension of $162.78. Support at fib 23.6% of $109.15 and the SMA50 at $93.73. Vol_vs_avg at 0.08x is very low — this thin-volume move warrants caution.

NBIS (+8.9%) — $277.68 → $341.06 (+22.8% upside) Thesis: Nebius is in a multi-catalyst moment: competing to acquire Decart AI (against Amazon, NVIDIA, SpaceX — elite company), Wedbush calling rising data center pricing a tailwind, senator stock disclosures driving retail interest, and 210% YTD performance that’s become a self-reinforcing narrative. The $25.4B RPO from Cerebras indirectly validates the AI infrastructure pricing power argument that supports NBIS. This is genuine AI infrastructure build-out, not sympathy. Levels: Exit at fib 1.272 extension of $341.06. Support at fib 23.6% of $239.52 and SMA50 at $222.38. 47% weekly gain warrants caution on sizing.

RCAT (+8.8%) — $11.13 → $13.09 (+17.6% upside) Thesis: Trump’s 100% tariff on imported drones is a real policy catalyst that directly benefits U.S. drone manufacturers. Red Cat Holdings builds domestically and just appointed a new Divisional CEO for UAS operations — operational alignment ahead of what could be a major procurement cycle. However, RSI at 16.21 is a technical anomaly that suggests the data may be stale or there was a recent severe dip before today’s bounce. Analysts project 70%+ additional upside from current levels. Levels: Exit at fib 38.2% of $13.09 (resistance from the 6-month range). Support at $10.68 (fib 61.8%). The 6-month high of $17.00 is the longer-term target.

⚠️ Trump pump caveat: Tariff-driven rallies in industrial/defense names tend to front-run reality. These moves historically consolidate or fade within 48-72 hours as execution questions emerge. Size accordingly.

Headlines to Watch

“Nebius, CoreWeave Get Major AI Boost as Data Center Prices Keep Rising” (Wedbush) — Rising compute pricing is the oxygen that sustains NBIS, CBRS, and the broader AI infrastructure trade; if pricing plateaus, this theme reverses hard.
“Anthropic Expects Mind-Blowing $200 Billion Revenue in 2028 as IPO Looms” — The AI hype cycle is being fueled by eye-popping projections; this keeps sentiment bid but also means any disappointment in AI monetization data (usage, pricing, churn) could trigger a sentiment cascade across all AI names.
“Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Lower Rate Hike Expectations” — Lower rate-hike probability is the macro tailwind today; watch Fed Minutes later this week for confirmation or reversal of this narrative.
“ChatGPT Disagrees With Michael Burry Over Nebius (NBIS)” — Burry’s bearish thesis on NBIS centers on unsustainable compute contract economics; when a mainstream media outlet literally asks ChatGPT to rebut Burry, we may be approaching peak retail euphoria in AI infrastructure names.
“Red Cat Stock Jumps on Trump Drone Tariff News — Analysts Think 70% More Upside” — The domestic drone manufacturing theme (RCAT, UMAC, ONDS) is a legitimate policy trade but watch for mean reversion as the initial excitement fades; position sizing is key.
“KLA Corporation Had a Tough Month: 60% Returns Will Come According to This Wall Street Stalwart” — KLAC weakness despite strong fundamentals is a tell on semiconductor equipment sector sentiment; worth monitoring as a potential rotation opportunity into semis infrastructure.
“High Dividend ETFs Beating the S&P 500 by 9 Points in 2026” — The factor rotation away from pure growth toward quality/dividend names is a 2026 theme that has legs if rates stay elevated; consider this when sizing high-multiple growth plays.

Claude’s Top Picks

AAOI (+15.5% today, +10.8% week) — $150.28 → $180.70 (+20.2% upside) Valuation: No formal comps provided, but with a multi-year Amazon contract and expanding margins, AAOI trades at a discount to pure-play optical networking peers given its recent 90-day pullback from $223. Upside: The Amazon multi-year supply agreement de-risks revenue visibility, the CFO Rosenblatt presentation tomorrow is a near-term catalyst, and the stock has technical room from current levels to the fib 23.6% resistance at $180.70. Risk: One analyst flags potential 93% overvaluation on DCF basis; if AI capex narratives cool or Amazon renegotiates terms, the stock could revisit the $133 fib 50% support quickly.

ARGX (+13.2% today, +11.2% week) — $963.41 → $1,052.67 (+9.2% upside) Valuation: Forward P/E of 24.6x vs peer median of 14.6x marks it EXPENSIVE, but a 59.3% revenue growth rate justifies the premium — PEG ratio of ~0.41 is actually deeply attractive for a large-cap biotech. Upside: Strategic M&A with Forte Biosciences adds a first-in-class pipeline asset while the core efgartigimod franchise continues to grow; at a 6-month high with RSI at 50, the technical setup supports further extension toward the $1,052 fib 1.272 target. Risk: M&A integration risk and the $2.2B cash outlay will compress near-term FCF; if Forte’s FB102 hits clinical snags post-acquisition, the premium disappears fast.

CBRS (+12.8% today, +7.4% week) — $246.97 → $277.43 (+12.3% upside) Valuation: Forward P/E of 192.9x vs peer median of 18.9x is objectively EXPENSIVE, but with 74.3% revenue growth and $25.4B in RPO, EV/Revenue is a better metric — the backlog represents years of locked-in demand. Upside: The post-earnings 12% dip that preceded today’s bounce created a better entry point; rising data center pricing (Wedbush thesis) and the AWS/AMD partnerships expand the addressable market meaningfully. Risk: Q3 guidance disappointed enough to tank the stock 12% last week — if sequential growth decelerates from the 103% YoY pace, the 192x forward P/E will compress violently; margin pressure is real and documented.

JCAP (+11.1% today, +13.1% week) — $24.00 → $26.71 (+11.3% upside) Valuation: No formal comps provided; debt purchaser at ~1x book on record portfolio deployment is historically reasonable for the specialty finance sector. Upside: Record forward flow commitments, 18% YoY collections growth, fresh dividend, and entry into Mexico’s debt-purchasing market are tangible operational catalysts — this is a clean fundamental story with no hype premium. Risk: RSI at 21.99 is extremely oversold (unusual for an 11% gainer — may reflect prior sharp selloff), and the 6-month high of $24.32 is nearly current price; breaking to new highs with conviction will require sustained execution delivery.

RCAT (+8.8% today, +20.9% week) — $11.13 → $13.09 (+17.6% upside) Valuation: Small-cap defense/drone manufacturer — no formal comps, but the tariff protection moat materially changes the competitive landscape and justifies a re-rating. Upside: 100% tariff on imported drones is structural policy protection, new UAS leadership consolidation signals operational focus, and analyst 70% upside targets have credibility given the domestic procurement pipeline. Risk: Trump tariff trades historically front-run reality by days to weeks — execution on actual government contracts is what matters, and RCAT has to prove it can ramp production to meet demand without the imported components that now cost twice as much.

Avoid

ETON — Already at a 6-month AND all-time high after a 44% single-day rip on top of 261% YTD gains; even if guidance is “conservative,” new buyers at $58-$60 are pricing in perfection with no margin of safety, and the vol_vs_avg of 0.2x signals thin conviction behind the move.

HTFL — Stock is trading at the newly revised fair value of ~$42 after a 69% 30-day surge and 36% single-day move; multiple analysts have already explicitly flagged it as “fully valued” and “overvalued,” with vol_vs_avg of 0.2x on the breakout — this is a classic “buy the rumor, sell the news” trap for chasers.

EYPT — Current price of $14.75 is dramatically below the 6-month high of $18.34 AND the SMA50 of $13.00 is also well below the 20-day low of $4.45 reflected in the technicals, suggesting extreme volatility and possible data inconsistency; the underlying numbers show a revenue beat of +102.8% but an EPS miss of -18.48%, and the 6-month technical structure (current price near the 6-month low despite the day’s gain) implies this is a damaged chart — high-risk binary play only.

WSB Sentiment Check

SNDK — WSB says: BULLISH (80% bullish), 167 mentions, 709 upvotes Claude says: PARTIALLY AGREE — SanDisk is riding the memory/storage AI data center wave alongside MU, and at $1,730 it’s sitting above the fib 38.2% support at $1,644 but well below the 6-month high of $2,335. The chart shows a recovery from lows but SMA50 at $1,655 is just below — if it holds that as support, the bull case to $1,908 (fib 23.6%) is technically valid. But 80% bullish consensus on WSB at a recovering high is often a fade signal — be careful with options sizing.

MU — WSB says: BULLISH (80% bullish), 163 mentions, 1,624 upvotes Claude says: AGREE — Micron at $1,007 is sitting right at the fib 23.6% support/resistance of $1,002 — a textbook test of this level. The HBM3E demand cycle for AI training chips is a multi-quarter tailwind, and the SMA50 at $960 provides a clean technical stop. 1,624 upvotes reflects genuine institutional interest, not just meme energy. The fib 1.272 extension at $1,455 is the medium-term target. This is one of the cleaner setups on the WSB list.

NVDA — WSB says: BULLISH (80% bullish), 85 mentions, 1,053 upvotes Claude says: AGREE WITH CAUTION — NVDA at $225.84 is at a 20-day high and 6-month high, with fib 1.272 extension at $254.64 as the next logical target. The AI infrastructure buildout thesis is intact and the SMA50 at $206.66 is a reasonable stop. However, at 1,053 upvotes with everyone already long, the marginal buyer is getting thinner. This is the right stock for the right reasons — just don’t expect another 50% in 3 months when it’s already at the top of its 6-month range.

NBIS — WSB says: BULLISH (80% bullish), 60 mentions, 134 upvotes Claude says: AGREE WITH SIZE DISCIPLINE — The Decart AI acquisition bid, Wedbush data center pricing thesis, and senator disclosure catalyst are real. Up 210% YTD and 47.7% in a week, the stock is extended but not at fib 1.618 yet ($410). The fib 1.272 at $341 is the rational near-term exit. Michael Burry’s bearish thesis on compute economics is worth respecting as a tail risk — don’t bet the house. The technicals support the bulls here; just size appropriately given the WSB retail crowding.

SPCX — WSB says: BULLISH (80% bullish), 51 mentions, 329 upvotes Claude says: DISAGREE — SPCX at $144.09 is well below its 6-month high of $211.39 and below every meaningful fib retracement level (fib 61.8% support at $147.66 has already broken to the downside). No SMA50 data available, which typically signals a newer instrument. There’s no company-specific news in the data to support this move — this looks like WSB crowding into a space/satellite ETF on narrative momentum, not fundamentals. With vol_vs_avg at 0.12x, the volume doesn’t support the conviction the 80% bullish reading implies. This is the most dangerous WSB pick of the five today.

Earnings Scorecard

POET — REPORTED | EPS: -$0.69 | Stock: +7.5% Sixth consecutive quarter of revenue growth with 2026 production ramp confirmed “on schedule” — the positive reaction is justified and modest given the Lumentum sympathy bid in photonics. The EPS loss isn’t concerning for an early-stage revenue ramp. Watch: not a buy-the-dip; it’s a hold-the-momentum if you own it.

ZIM — REPORTED | EPS: +$0.82 | Stock: +2.5% Muted reaction to positive EPS suggests shipping stocks are pricing in cyclical peak concerns. The +$0.82 EPS is solid but the 2.5% gain reflects limited upside surprise. Reaction justified; shipping is late-cycle and tariff uncertainty creates cargo routing volatility. Neutral.

KLAR — REPORTED | EPS: -$0.52 | Stock: -1.8% Klarna reported a loss as expected for a growth FinTech, but the -1.8% reaction to a three-week winning streak suggests profit-taking was overdue regardless of results. Analyst target of $24.55 vs current price implies street still sees upside. Modest selloff overdone — buy-the-dip if the BNPL macro thesis holds.

ROST — REPORTED | EPS: +$7.16 | Stock: -1.4% Off-price retail printed solid numbers but couldn’t hold gains in a market where HD, LOW, and TGT all declined post-earnings. This is sector-level pressure, not company-specific failure. Analyst target of $255 implies meaningful upside from current levels. Reaction overdone — off-price retail should outperform in tariff/inflation environment. Quietly accumulate.

FN — REPORTED | EPS: +$11.63 | Stock: +1.3% Fabrinet’s solid optical interconnect manufacturing quarter gets a modest positive reaction — consistent with its role as a “picks and shovels” beneficiary of AI infrastructure demand. Analyst target of $732 implies significant upside. Justified and understated — this is a quality name getting less attention than the flashier AI plays.

LOW — REPORTED | EPS: +$11.82 | Stock: -1.2% Lowe’s results in the context of a weak housing market and tariff cost-pass-through uncertainty. The -1.2% is understandable given consumer discretionary headwinds. Analyst target of $261 is close to current levels — limited near-term upside. Reaction justified; housing renovation cycle is soft.

HD — REPORTED | EPS: +$14.10 | Stock: -1.2% Same read as LOW — solid numbers in a difficult housing backdrop, market is looking at forward guidance more than trailing EPS. Analyst target of $374 offers moderate upside. Reaction justified; wait for a housing market catalyst before getting excited.

BIDU — REPORTED | EPS: -$0.16 | Stock: -1.1% Baidu’s negative EPS and “China Tech Earnings Renew Focus on Hardware Stocks Over Internet” headline tell the story — China internet names are being de-rated in favor of hardware. The analyst target of $167 is well above current prices but China regulatory and geopolitical risk premiums are real. Avoid until China tech sentiment structurally improves.

TJX — REPORTED | EPS: +$5.14 | Stock: -0.9% TJX is the gold standard off-price retailer and a -0.9% move on earnings that beat estimates is a non-event. Analyst target of $177 implies upside. Reaction unjustified (mild sell) — TJX benefits directly from tariff-driven consumer trade-down. Mild buy-the-dip.

WMT — REPORTED | EPS: +$2.84 | Stock: -0.2% Walmart essentially flat post-earnings after guiding cautiously on tariff cost impacts. The -0.2% is noise. Analyst target of $138 is very close to current prices — the stock is fully valued after a strong run. Reaction justified; hold but don’t chase.

TGT — REPORTED | EPS: +$7.57 | Stock: -0.5% Target continues to struggle with traffic and discretionary spending weakness vs. Walmart and off-price competitors. Analyst target of $143 is barely above current prices. Reaction justified; Target is a structural share-loss story vs. WMT and off-price — avoid.

BABA — REPORTED | EPS: +$6.52 | Stock: +0.6% Alibaba barely positive on solid EPS — reflects ongoing China risk premium and geopolitical uncertainty suppressing multiple expansion. Reaction accurately muted; this is a show-me story that requires sustained profitability improvement and regulatory clarity.

This brief is for informational purposes and reflects analysis based on available data as of 2026-08-17. Not financial advice.